Reactive capillary hemangiomas: a novel dermatologic toxicity following anti-PD-1 treatment with SHR-1210

References

1. 1.↵
   2. Naidoo J,
   3. Page DB,
   4. Li BT,
   5. Connell LC,
   6. Schindler K,
   7. Lacouture ME, et al.

   Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies. Ann Oncol. 2016; 27: 1362.

   OpenUrlCrossRefPubMed
2. 2.↵
   2. Belum VR,
   3. Benhuri B,
   4. Postow MA,
   5. Hellmann MD,
   6. Lesokhin AM,
   7. Segal NH, et al.

   Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor. Eur J Cancer. 2016; 60: 12–25.

   OpenUrl
3. 3.↵
   2. Ciccarese C,
   3. Alfieri S,
   4. Santoni M,
   5. Santini D,
   6. Brunelli M,
   7. Bergamini C, et al.

   New toxicity profile for novel immunotherapy agents: focus on immune-checkpoint inhibitors. Expert Opin Drug Metab Toxicol. 2016; 12: 57–75.

   OpenUrl
4. 4.↵
   2. Postow MA,
   3. Callahan MK,
   4. Wolchok JD.

   Immune checkpoint blockade in cancer therapy. J Clin Oncol. 2015; 33: 1974–82.

   OpenUrlAbstract/FREE Full Text
5. 5.↵
   2. Curry JL,
   3. Tetzlaff MT,
   4. Nagarajan P,
   5. Drucker C,
   6. Diab A,
   7. Hymes SR, et al.

   Diverse types of dermatologic toxicities from immune checkpoint blockade therapy. J Cutan Pathol. 2017; 44: 158–76.

   OpenUrl
6. 6.↵
   2. Huang J,
   3. Xu BH,
   4. Mo HN,
   5. Zhang WL,
   6. Chen XL,
   7. Wu DW, et al.

   Safety, activity, and biomarkers of SHR-1210, an anti-PD-1 antibody, for patients with advanced esophageal carcinoma. Clin Cancer Res. 2018; 24: 1296–304.

   OpenUrlAbstract/FREE Full Text
7. 7.↵
   2. Mo HN,
   3. Huang J,
   4. Xu JC,
   5. Chen XL,
   6. Wu DW,
   7. Qu D, et al.

   Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. Br J Cancer. 2018; 119: 538–45.

   OpenUrlPubMed
8. 8.↵
   2. Chen AP,
   3. Setser A,
   4. Anadkat MJ,
   5. Cotliar J,
   6. Olsen EA,
   7. Garden BC, et al.

   Grading dermatologic adverse events of cancer treatments: the Common Terminology Criteria for Adverse Events Version 4.0. J Am Acad Dermatol. 2012; 67: 1025–39.

   OpenUrlCrossRefPubMed
9. 9.↵
   2. George A,
   3. Mani V,
   4. Noufal A.

   Update on the classification of hemangioma. J Oral Maxillofac Pathol. 2014; 18: S117–20.

   OpenUrl
10. 10.↵
    2. Luu M,
    3. Frieden IJ.

    Haemangioma: clinical course, complications and management. Br J Dermatol. 2013; 169: 20–30.

    OpenUrlCrossRefPubMed
11. 11.↵
    2. Ji Y,
    3. Chen SY,
    4. Li K,
    5. Li L,
    6. Xu C,
    7. Xiang B.

    Signaling pathways in the development of infantile hemangioma. J Hematol Oncol. 2014; 7: 13.

    OpenUrl
12. 12.↵
    2. Laken PA.

    Infantile Hemangiomas: Pathogenesis and review of propranolol use. Adv Neonatal Care. 2016; 16: 135–42.

    OpenUrl
13. 13.↵
    2. Chang LC,
    3. Haggstrom AN,
    4. Drolet BA,
    5. Baselga E,
    6. Chamlin SL,
    7. Garzon MC, et al.

    Growth characteristics of infantile hemangiomas: implications for management. Pediatrics. 2008; 122: 360–7.

    OpenUrlAbstract/FREE Full Text
14. 14.↵
    2. Harris MN,
    3. Desai R,
    4. Chuang TY,
    5. Hood AF,
    6. Mirowski GW.

    Lobular capillary hemangiomas: An epidemiologic report, with emphasis on cutaneous lesions. J Am Acad Dermatol. 2000; 42: 1012–6.

    OpenUrlCrossRefPubMed
15. 15.↵
    2. Fujiwara C,
    3. Motegi SI,
    4. Sekiguchi A,
    5. Amano H,
    6. Ishikawa O.

    Pyogenic granuloma possibly associated with capecitabine therapy. J Dermatol. 2017; 44: 1329–31.

    OpenUrl
16. 16.
    2. Paul LJ,
    3. Cohen PR.

    Paclitaxel-associated subungual pyogenic granuloma: report in a patient with breast cancer receiving paclitaxel and review of drug-induced pyogenic granulomas adjacent to and beneath the nail. J Drugs Dermatol. 2012; 11: 262–8.

    OpenUrlPubMed
17. 17.
    2. Massa A,
    3. Antunes A,
    4. Varela P.

    Pyogenic granuloma in a patient on Gefitinib. Acta Med Port. 2016; 29: 416.

    OpenUrl
18. 18.↵
    2. Simmons BJ,
    3. Chen L,
    4. Hu S.

    Pyogenic granuloma association with isotretinoin treatment for acne. Australas J Dermatol. 2016; 57: e144–5.
19. 19.↵
    2. Palmero ML,
    3. Pope E.

    Eruptive pyogenic granulomas developing after drug hypersensitivity reaction. J Am Acad Dermatol. 2009; 60: 855–7.

    OpenUrlPubMed
20. 20.↵
    2. Aliağaoğlu C,
    3. Bakan V,
    4. Atasoy M,
    5. Toker S.

    Pyogenic granuloma with multiple and satellite involvement after a burn in a 5-year-old child. J Dermatol. 2006; 33: 150–2.

    OpenUrlPubMed
21. 21.↵
    2. Patil A,
    3. Pattanshetti C,
    4. Varekar A,
    5. Huddar SB.

    Oral capillary haemangioma mimicking pyogenic granuloma: a challenge for diagnosis and management. BMJ Case Rep. 2013; 14: 2013.

    OpenUrl
22. 22.↵
    2. Weber JS,
    3. Yang JC,
    4. Atkins MB,
    5. Disis ML.

    Toxicities of immunotherapy for the practitioner. J Clin Oncol. 2015; 33: 2092–9.

    OpenUrlAbstract/FREE Full Text
23. 23.↵
    2. Hua C,
    3. Boussemart L,
    4. Mateus C,
    5. Routier E,
    6. Boutros C,
    7. Cazenave H, et al.

    Association of vitiligo with tumor response in patients with metastatic melanoma treated with pembrolizumab. JAMA Dermatol. 2016; 152: 45–51.

    OpenUrl
24. 24.
    2. Byrne KT,
    3. Turk MJ.

    New perspectives on the role of vitiligo in immune responses to melanoma. Oncotarget. 2011; 2: 684–94.

    OpenUrlCrossRefPubMedWeb of Science
25. 25.↵
    2. Sanlorenzo M,
    3. Vujic I,
    4. Daud A,
    5. Algazi A,
    6. Gubens M,
    7. Luna SA, et al.

    Pembrolizumab cutaneous adverse events and their association with disease progression. JAMA Dermatol. 2015; 151: 1206–12.

    OpenUrlPubMed
26. 26.↵
    2. Bonigen J,
    3. Raynaud-Donzel C,
    4. Hureaux J,
    5. Kramkimel N,
    6. Blom A,
    7. Jeudy G, et al.

    Anti-PD1-induced psoriasis: a study of 21 patients. J Eur Acad Dermatol Venereol. 2017; 31: e254–7.